Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tecarfarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 known ✓ | Q9BQB6 | 8/20 | 0.62 |
| ▸ | NQO1 | P15559 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tecarfarin SCHEMBL1647984 | 1.00 | VKORC1 (0.62) | VKORC1NQO1ALDH1A1MEN1KMT2A | |
| SCHEMBL4589169 | 0.90 | VKORC1 (0.59) | VKORC1NQO1ALDH1A1MEN1KMT2A | |
| Tecarfarin SCHEMBL31681436 | 0.88 | VKORC1 (0.47) | VKORC1NQO1ALDH1A1MEN1KMT2A | |
| SCHEMBL13498436 | 0.85 | VKORC1 (0.62) | VKORC1NQO1ALDH1A1MEN1KMT2A | |
| SCHEMBL14078682 | 0.84 | VKORC1 (0.60) | VKORC1NQO1ALDH1A1MEN1KMT2A | |
| SCHEMBL12778653 | 0.84 | VKORC1 (0.60) | VKORC1NQO1ALDH1A1MEN1KMT2A | |
| SCHEMBL1648184 | 0.83 | VKORC1 (0.72) | VKORC1NQO1ALDH1A1MEN1KMT2A | |
| SCHEMBL1649093 | 0.83 | VKORC1 (0.62) | VKORC1NQO1ALDH1A1MEN1KMT2A | |
| SCHEMBL3171054 | 0.83 | VKORC1 (0.61) | VKORC1NQO1ALDH1A1MEN1KMT2A | |
| SCHEMBL1648109 | 0.83 | VKORC1 (0.59) | VKORC1NQO1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276120-A1 | METHOD FOR PREVENTING COAGULATION IN PATIENTS WITH IMPLANTED CARDIAC DEVICES | Cadrenal Therapeutics, Inc. | 2025-09-04 | — | — | US | claimed |
| US-11826366-B2 | Composition and methods for preventing or reducing the incidence of transient ischemic attacks | MOREHOUSE SCHOOL OF MEDICINE (US) | 2023-11-28 | — | — | US | claimed |
| CN-114712361-A | Compositions and methods for preventing or reducing the incidence of transient ischemic attacks | 莫尔豪斯医学院 | 2022-07-08 | — | — | CN | claimed |
| US-11318331-B2 | Pulmonary hypertension treatment | SONIVIE LTD. (IL) | 2022-05-03 | — | — | US | claimed |
| US-20220047586-A1 | COMPOSITION AND METHODS FOR PREVENTING OR REDUCING THE INCIDENCE OF TRANSIENT ISCHEMIC ATTACKS | MOREHOUSE SCHOOL OF MEDICINE | 2022-02-17 | — | — | US | claimed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250276120-A1 | METHOD FOR PREVENTING COAGULATION IN PATIENTS WITH IMPLANTED CARDIAC DEVICES | Cadrenal Therapeutics, Inc. | 2025-09-04 | — | — | US | disclosed |
| WO-2025184627-A1 | METHOD FOR PREVENTING COAGULATION IN PATIENTS WITH IMPLANTED CARDIAC DEVICES | Cadrenal Therapeutics, Inc. (US) | 2025-09-04 | — | — | WO | disclosed |
| US-20250276120-A1 | METHOD FOR PREVENTING COAGULATION IN PATIENTS WITH IMPLANTED CARDIAC DEVICES | Cadrenal Therapeutics, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-12390422-B2 | Transdermal drug delivery patch, drug delivery system and drug delivery | Passport Technologies, Inc. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-11318331-B2 | Pulmonary hypertension treatment | SONIVIE LTD. (IL) | 2022-05-03 | — | — | US | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| CN-114269330-A | Transdermal drug delivery patch, drug delivery system, and drug delivery method | 帕斯帕特技术有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
| US-20220047586-A1 | COMPOSITION AND METHODS FOR PREVENTING OR REDUCING THE INCIDENCE OF TRANSIENT ISCHEMIC ATTACKS | MOREHOUSE SCHOOL OF MEDICINE | 2022-02-17 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | VKORC1 72/4885NQO1 110/4885ALDH1A1 793/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | VKORC1 3884/4885NQO1 2800/4885ALDH1A1 3843/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | VKORC1 3884/4885NQO1 2800/4885ALDH1A1 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.